The University of Utah proposes to participate as a member of the Children's Cancer Study Group (CCSG) in the scientific design and execution of cooperative clinical research studies of childhood malignant neoplastic dieases. Utah's multi-disciplinary team of investigators have participated actively in CCSG for sixteen consecutive years. For more than a decade, Dr. Eugene Lahey led Utah's CCSG effort. In 1980, Dr. Richard O'Brien became Utah's CCSG principal investigator. He recruited a number of younger investigators with outstanding potential to supplement the experienced contributors to Utah's CCSG effort. Over the past three years Utah has aggressively enhanced its record of scientific and leadership contributions to CCSG. Dr. O'Brien, a member of the CCSG Late Effects Committee, is chairman of a proposed CCSG study (CCG-105N) expected to open for patient entry in April 1984, which will prospectively evaluate the neuropsychological effects of acute lymphoblastic leukemia (ALL) and its therapy. Dr. O'Brien is a member of a new, first line ALL study (CCG-105) and is also a member of two other new CCSG studies - Advanced Hodgkin's Disease (CCG-521) and Good Risk Medulloblastoma (CCG-923). Each of these studies address questions concerning possible late effects of therapy, an area of investigation in which Dr. O'Brien has special interest. Dr. Carl Kjeldsberg has joined Dr. John Wilson as major pathologists for CCSG lymphoma studies and they are responsible for """"""""rapid review"""""""" of all NHL specimens. As a result, Utah serves as a Central Reference Pathology Laboratory for many of the CCSG lymphoma studies. In addition, their investigative work is defining the importance of histopathology in disease management. Dr. Dale Johnson is Vice Chairman of the Surgical Steering Committee, a member of the rhabdomyosarcoma study, a new relapsed ALL study (CCG-112) and has written the surgical guidelines for testicular biopsy for all ALL patients. Consequently, in the past three years under new leadership, there has been an impressive resurgance of Utah's scientific contributions to CCSG. Four Utah investigators are now key participants in more than half dozen new, first line CCSG studies, the results of which should be realized over the next few years. This recent record demonstrates the important role that Utah investigators play in the current and, particularly, the future scientific goals and accomplishments of CCSG.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Medicine
Salt Lake City
United States
Zip Code
Lin, Zi-Jing; Li, Lin; Cazzell, Mary et al. (2014) Atlas-guided volumetric diffuse optical tomography enhanced by generalized linear model analysis to image risk decision-making responses in young adults. Hum Brain Mapp 35:4249-66
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Adamson, P C; Widemann, B C; Reaman, G H et al. (2001) A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. Clin Cancer Res 7:3034-9
Cooper, R; Khakoo, Y; Matthay, K K et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-9
Kammen, B F; Matthay, K K; Pacharn, P et al. (2001) Pulmonary metastases at diagnosis of neuroblastoma in pediatric patients: CT findings and prognosis. AJR Am J Roentgenol 176:755-9